Comparison of clinical, radiologic and pathologic response rates of neoadjuvant chemotherapy regimen containing doxorubicin and cyclophosphamide with paclitaxel and gemcitabine in locally advanced breast cancer

Vice chancellor for research, Shiraz University of Medical Sciences0 个研究点目标入组 70 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•A) positive pathology of breast cancer; Karnofsky performance status at least: 70; locally advanced breast cancer; age< 65 Years old; normal cardiac and liver and bone marrow function; normal and acceptable cardiac evaluation in high risk patients or past medical history of cardiac problem; filling the informed consent by patient.
•B) Exclusion criteria: receiving previous chemotherapy for breast cancer; clinical or pathological positive evidence of metastasis; underling disease which can’t receive chemotherapy; known contraindication for chemotherapy agent (taxan reaction); sever cardiac problem history such as heart failure, chest pain which needs medication, sever cardiac valve disease, myocardial infarction, uncontrolled blood pressure (systolic pressure above 180 mm/Hg and diastolic pressure above 100 mm/Hg); refusing treatment by patient.

发起方

Vice chancellor for research, Shiraz University of Medical Sciences